Bromine-rich Zinc Bromides: Zn₆Br₁₂(18-crown-6)₂×(Br₂)₅, Zn₄Br₈(18-crown-6)₂×(Br₂)₃, and Zn₆Br₁₂(18-crown-6)₂×(Br₂)₂

The bromine-rich zinc bromides Zn6Br12(18-crown-6)2×(Br2)5 (1), Zn4Br8(18-crown-6)2×(Br2)3 (2), and Zn6Br12(18-crown-6)2×(Br2)2 (3) are prepared by reaction of ZnBr2, 18-crown-6, and elemental bromine in the ionic liquid [MeBu3N]­[N­(Tf)2] (N­(Tf)2 = bis­(trifluoromethylsulfonyl)­amide). Zn6Br12(18-crown-6)2×(Br2)5 (1) is formed instantaneously by the reaction. Even at room temperature, compound 1 releases bromine, which was confirmed by thermogravimetry (TG) and mass spectrometry (MS). The release of Br2 can also be directly followed by the color and density of the title compounds. With controlled conditions (2 weeks, 25 °C, absence of excess Br2) Zn6Br12(18-crown-6)2×(Br2)5 (1) slowly releases bromine with conconcurrent generation of Zn4Br8(18-crown-6)2×(Br2)3 (2) (in ionic liquid) and Zn6Br12(18-crown-6)2×(Br2)2 (3) (in inert oil). All bromine-rich zinc bromides contain voluminous uncharged (e.g., Zn3Br6(18-crown-6), Zn2Br4(18-crown-6)) or ionic (e.g., [Zn2Br3(18-crown-6)]+, [(Zn2Br6)×(Br2)2]2–) building units with dibromine molecules between the Zn oligomers and partially interconnecting the Zn-containing building units. Due to the structural similarity, the bromine release is possible via crystal-to-crystal transformation with retention of the crystal shape

Bromine-rich Zinc Bromides: Zn₆Br₁₂(18-crown-6)₂×(Br₂)₅, Zn₄Br₈(18-crown-6)₂×(Br₂)₃, and Zn₆Br₁₂(18-crown-6)₂×(Br₂)₂

The bromine-rich zinc bromides Zn₆Br₁₂(18-crown-6)₂×(Br₂)₅ (<b>1</b>), Zn₄Br₈(18-crown-6)₂×(Br₂)₃ (<b>2</b>), and Zn₆Br₁₂(18-crown-6)₂×(Br₂)₂ (<b>3</b>) are prepared by reaction of ZnBr₂, 18-crown-6, and elemental bromine in the ionic liquid [MeBu₃N]­[N­(Tf)₂] (N­(Tf)₂ = bis­(trifluoromethylsulfonyl)­amide). Zn₆Br₁₂(18-crown-6)₂×(Br₂)₅ (<b>1</b>) is formed instantaneously by the reaction. Even at room temperature, compound <b>1</b> releases bromine, which was confirmed by thermogravimetry (TG) and mass spectrometry (MS). The release of Br₂ can also be directly followed by the color and density of the title compounds. With controlled conditions (2 weeks, 25 °C, absence of excess Br₂) Zn₆Br₁₂(18-crown-6)₂×(Br₂)₅ (<b>1</b>) slowly releases bromine with conconcurrent generation of Zn₄Br₈(18-crown-6)₂×(Br₂)₃ (<b>2</b>) (in ionic liquid) and Zn₆Br₁₂(18-crown-6)₂×(Br₂)₂ (<b>3</b>) (in inert oil). All bromine-rich zinc bromides contain voluminous uncharged (e.g., Zn₃Br₆(18-crown-6), Zn₂Br₄(18-crown-6)) or ionic (e.g., [Zn₂Br₃(18-crown-6)]⁺, [(Zn₂Br₆)×(Br₂)₂]^2–) building units with dibromine molecules between the Zn oligomers and partially interconnecting the Zn-containing building units. Due to the structural similarity, the bromine release is possible via crystal-to-crystal transformation with retention of the crystal shape

Source Data for 'A clinically applicable connectivity signature for glioblastoma includes the tumor network driver <i>CHI3L1</i>'<i> </i>

Tumor microtubes (TMs) connect glioma cells to a network with considerable relevance for tumor progression and therapy resistance. However, the determination of TM-interconnectivity in individual tumors is challenging and the impact on patient survival unresolved. Here, we establish a connectivity signature from single-cell RNA-sequenced (scRNA-Seq) xenografted primary glioblastoma (GB) cells using a dye uptake methodology, and validate it with recording of cellular calcium epochs and clinical correlations. Astrocyte-like and mesenchymal-like GB cells have the highest connectivity signature scores in scRNA-sequenced patient-derived xenografts and patient samples. In large GB cohorts, TM-network connectivity correlates with the mesenchymal subtype and dismal patient survival. CHI3L1 gene expression serves as a robust molecular marker of connectivity and functionally influences TM networks. The connectivity signature allows insights into brain tumor biology, provides a proof-of-principle that tumor cell TM-connectivity is relevant for patients’ prognosis, and serves as a robust prognostic biomarker. ​</p